News

The vice president and senior global program lead for Hematology and Cell Therapy at BMS gave clinical commentary on encouraging phase 1 findings of CD19-XT in progressive and relapsing multiple sclerosis.

In both HERCULES and GEMINI trials, tolebrutinib reduced the risk of 6-month confirmed disability worsening, especially in participants with at least 4 baseline paramagnetic rim lesions.

With a scheduled PDUFA date of August 31, 2025, deramiocel looks to become the first marketed treatment for cardiomyopathy in DMD, one of the leading causes of death in this patient population.

Originally approved in 2007, eculizumab (Soliris; Alexion/AstraZeneca) is now available to treat both adult and pediatric patients with generalized myasthenia gravis, becoming the first available option for younger patients with the disease.

The pediatric neurologist at Children’s Hospital of Philadelphia gave perspective on some of the main issues the clinical community is figuring out with gene therapies and their integration to clinical practice. [WATCH TIME: 3 minutes]

Overall, treatment with the anti-tau monoclonal antibody resulted in no serious or severe adverse events, with additional results expected to be presented at an upcoming scientific conference.

Glatiramer acetate depot treatment showed stability in EDSS scores over 3 years, suggesting halted progression in patients with primary progressive MS.

At the 2025 ACTRIMS Forum, the system chief of neuroimmunology and multiple sclerosis at OhioHealth discussed the need for better tools to detect MS progression. [WATCH TIME: 3 minutes]

The director of the MS and Demyelinating Disease Center at Texas Tech University Health Sciences Center talked about early diagnosis, timely treatment, and minimizing therapy transition gaps to prevent severe disability in patients with NMOSD. [WATCH TIME: 4 minutes]

After 24 months after switching to cladribine, 100% of patients with relapsing MS remained free from T1 gadolinium-enhancing lesions, with no reported cases of PML or rebound disease activity.

The assistant professor of neurology and neurosurgery at McGill University discussed the role of paramagnetic rim lesions as potential biomarkers of compartmentalized inflammation in MS. [WATCH TIME: 4 minutes]

The thrombolytic treatment, branded as TNKase and approved for adults, is administered as a 5-second IV bolus, upping the speed and simplicity of the 60-minute infusion of the previously approved alteplase (Activase; Genentech).

The founder and executive director of the Sumaira Foundation talked about how the landscape of NMOSD treatment has drastically improved with FDA-approved therapies, while noting that accessibility and awareness remain significant challenges. [WATCH TIME: 4 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

The assistant professor of medicine at the University of Toronto talked about emerging research on how prodromal symptoms may aid in the early identification of multiple sclerosis and neuromyelitis optica spectrum disorder. [WATCH TIME: 6 minutes]

The 80 mg QD dosage, which showed the greatest efficacy in lesion reduction (92.3% at 24 weeks), will be used in phase 3 progressive MS studies.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on dementia.

At the 2025 ACTRIMS Forum, the assistant professor of neuroimmunology at McGill University talked about examining immune cell signatures to track disease worsening in multiple sclerosis. [WATCH TIME: 4 minutes]

A new phase 1 study will investigate the safety and biological effects of light therapy as a potential approach to alleviating fatigue in patients with progressive multiple sclerosis.

The autoimmune neurology program director at the University of Colorado highlighted the potential of CAR T-cell therapy for treating autoimmune neurologic diseases like progressive forms of multiple sclerosis. [WATCH TIME: 3 minutes]

Neurology News Network. for the week ending March 1, 2025. [WATCH TIME: 3 minutes]

The autoimmune neurology program director at the University of Colorado talked about the emerging use of CAR T-cell therapy, a breakthrough from oncology, now being explored in autoimmune neurologic diseases like multiple sclerosis. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 28, 2025.

The vice president and senior global program lead for Hematology and Cell Therapy at BMS provided an overview behind the mechanism and early phase 1 data of BMS-986353 in various forms of multiple sclerosis. [WATCH TIME: 4 minutes]

Amber Freed, founder of SLC6A1 Connect, shared her personal journey and advocacy efforts to raise awareness for SLC6A1, a rare genetic epilepsy, in honor of Rare Disease Day.

Mary Schroth, MD, FAAP, FCCP, chief medical officer at Cure SMA, shed insight on the advances and promise for treating spinal muscular atrophy, in the context of Rare Disease Day.

After 4 years of treatment, those on cladribine demonstrated a correlation between sustained health-related quality of life, specifically physical and mental health, and cognition.

The executive vice president of research at National MS Society talked about how advancements in the field of neurology are shaping new approaches to diagnosing, monitoring, and treating multiple sclerosis. [WATCH TIME: 5 minutes]

Overall, 81.6% of patients preferred ocrelizumab over other MS treatments, with 98.1% satisfied with it overall by week 48.

The executive vice president of research at National MS Society discussed the role of compartmentalized inflammation, microglial interactions, and emerging therapeutic targets in multiple sclerosis. [WATCH TIME: 4 minutes]